antidiabeticos orales. elisa fernández
TRANSCRIPT
![Page 1: Antidiabeticos orales. Elisa Fernández](https://reader033.vdocuments.net/reader033/viewer/2022051400/5591742a1a28abcd5b8b466f/html5/thumbnails/1.jpg)
Elisa Fernández LópezR1 Farmacia hospitalaria
![Page 2: Antidiabeticos orales. Elisa Fernández](https://reader033.vdocuments.net/reader033/viewer/2022051400/5591742a1a28abcd5b8b466f/html5/thumbnails/2.jpg)
1) INTRODUCCION
2) DOCUMENTO CONSENSO
3) FARMACOS UTILIZADOS
4) ANTIDIABETICOS ORALES EN EL HOSPITAL
![Page 3: Antidiabeticos orales. Elisa Fernández](https://reader033.vdocuments.net/reader033/viewer/2022051400/5591742a1a28abcd5b8b466f/html5/thumbnails/3.jpg)
1. Resistencia periférica a la acción de la insulina. 2.Sobreesfuerzo pancreático fallo progresivo
secreción insulina. 3. Extasis pancreático insulino-dependencia.
![Page 4: Antidiabeticos orales. Elisa Fernández](https://reader033.vdocuments.net/reader033/viewer/2022051400/5591742a1a28abcd5b8b466f/html5/thumbnails/4.jpg)
ADA European Association for the study of diabetes MSC Grupo de estudio de la Diabetes en Atencion
Primaria de la Salud.
Documento consenso
![Page 5: Antidiabeticos orales. Elisa Fernández](https://reader033.vdocuments.net/reader033/viewer/2022051400/5591742a1a28abcd5b8b466f/html5/thumbnails/5.jpg)
Objetivos control (lipidograma,TA,IMC,tabaco)
HbA1c < 6,5% Fases iniciales, <70 a., sin
complicaciones/patologías asociadas
HbA1c < 7,5% Pacientes con años de evolución, politerapia
Inercia terapéutica Escalonamiento terapéutico
![Page 6: Antidiabeticos orales. Elisa Fernández](https://reader033.vdocuments.net/reader033/viewer/2022051400/5591742a1a28abcd5b8b466f/html5/thumbnails/6.jpg)
![Page 7: Antidiabeticos orales. Elisa Fernández](https://reader033.vdocuments.net/reader033/viewer/2022051400/5591742a1a28abcd5b8b466f/html5/thumbnails/7.jpg)
![Page 8: Antidiabeticos orales. Elisa Fernández](https://reader033.vdocuments.net/reader033/viewer/2022051400/5591742a1a28abcd5b8b466f/html5/thumbnails/8.jpg)
Disminuyen R a insulina Secretagogos
Disminuyen absorción de glucosa
Sistema incretinas
![Page 9: Antidiabeticos orales. Elisa Fernández](https://reader033.vdocuments.net/reader033/viewer/2022051400/5591742a1a28abcd5b8b466f/html5/thumbnails/9.jpg)
Antihiperglucemiante Perfil lipídico AP 2-3/d,no pp, noBT, ↑renal. RA: GI, acidosis láctica, absorción B12 ↓peso
Antihiper.10-12 w ↑peso, anemias,
fracturas, ICC Asociación Poco evaluado a largo
plazo. Cáncer vejiga
METFORMINA GLITAZONAS
acidosis láctica
![Page 10: Antidiabeticos orales. Elisa Fernández](https://reader033.vdocuments.net/reader033/viewer/2022051400/5591742a1a28abcd5b8b466f/html5/thumbnails/10.jpg)
SULFONILUREAS
DERIVADOS DE MEGLITINIDA
r. SUR1 gr.sulfona ↑ union pp I.R /I.H Interacciones FD: GC, betabloq. Intensas y frecuentes
hipoglucemias ↑peso, HS
Glibenclamida (Daonil) ↑PGliclazida (Diamicron) L.P
r. SUR1 “reguladores posprandiales de
la glucemia” Meglitinida ↓riesgo hipoglucemias ↑union pp ↓ t1/2 por M.H: ojo IR/no pr.IH ↑peso
![Page 11: Antidiabeticos orales. Elisa Fernández](https://reader033.vdocuments.net/reader033/viewer/2022051400/5591742a1a28abcd5b8b466f/html5/thumbnails/11.jpg)
![Page 12: Antidiabeticos orales. Elisa Fernández](https://reader033.vdocuments.net/reader033/viewer/2022051400/5591742a1a28abcd5b8b466f/html5/thumbnails/12.jpg)
![Page 13: Antidiabeticos orales. Elisa Fernández](https://reader033.vdocuments.net/reader033/viewer/2022051400/5591742a1a28abcd5b8b466f/html5/thumbnails/13.jpg)
Acarbosa y Miglitol Inhibidores alfa-glucosidasas intestinales Coadyuvante “Rescate” de intolerantes a la glucosa Intolerancia GI.
![Page 14: Antidiabeticos orales. Elisa Fernández](https://reader033.vdocuments.net/reader033/viewer/2022051400/5591742a1a28abcd5b8b466f/html5/thumbnails/14.jpg)
Mimeticos GLP-1 (incretina) Inhibidores DPP-4
ExenatidaSCAlternativa a insulina en DMII no
controlada con ADO
Sitagliptina VidagliptinaVO2ª linea DMII
![Page 15: Antidiabeticos orales. Elisa Fernández](https://reader033.vdocuments.net/reader033/viewer/2022051400/5591742a1a28abcd5b8b466f/html5/thumbnails/15.jpg)
![Page 16: Antidiabeticos orales. Elisa Fernández](https://reader033.vdocuments.net/reader033/viewer/2022051400/5591742a1a28abcd5b8b466f/html5/thumbnails/16.jpg)
![Page 17: Antidiabeticos orales. Elisa Fernández](https://reader033.vdocuments.net/reader033/viewer/2022051400/5591742a1a28abcd5b8b466f/html5/thumbnails/17.jpg)
![Page 18: Antidiabeticos orales. Elisa Fernández](https://reader033.vdocuments.net/reader033/viewer/2022051400/5591742a1a28abcd5b8b466f/html5/thumbnails/18.jpg)
Efectos adversos Inicio lento de acción y larga duración ↓flexibilidad para adaptarse a requerimientos
cambiantes( omisión comidas,GC,Stress..)▪ Hipoglucemias▪ Intolerancia gástrica/acidosis láctica▪Eficacia limitada
![Page 19: Antidiabeticos orales. Elisa Fernández](https://reader033.vdocuments.net/reader033/viewer/2022051400/5591742a1a28abcd5b8b466f/html5/thumbnails/19.jpg)
Pauta correctora sc
Basal bolus0,4UI/hg/dia
Basal bolus0,5UI/kg/dia
70-130< 180
140-180
![Page 20: Antidiabeticos orales. Elisa Fernández](https://reader033.vdocuments.net/reader033/viewer/2022051400/5591742a1a28abcd5b8b466f/html5/thumbnails/20.jpg)
GRACIAS POR SU ATENCION